Cargando…
Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial
BACKGROUND: Each year, an estimated 15 million babies are born preterm, a global burden borne disproportionately by families in lower-income countries. Maternal HIV infection increases a woman’s risk of delivering prematurely, and antiretroviral therapy (ART) may compound this risk. While prenatal p...
Autores principales: | Price, Joan T., Vwalika, Bellington, Freeman, Bethany L., Cole, Stephen R., Mulenga, Helen B., Winston, Jennifer, Mbewe, Felistas M., Chomba, Elwyn, Mofenson, Lynne M., Rouse, Dwight J., Goldenberg, Robert L., Stringer, Jeffrey S. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391830/ https://www.ncbi.nlm.nih.gov/pubmed/30813934 http://dx.doi.org/10.1186/s12884-019-2224-8 |
Ejemplares similares
-
Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial
por: Price, Joan T, et al.
Publicado: (2021) -
Comparison of intravaginal progesterone gel and intramuscular 17-α-hydroxyprogesterone caproate in luteal phase support
por: SATIR, FUNDA, et al.
Publicado: (2013) -
Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection
por: Chollet, John L., et al.
Publicado: (2012) -
Pharmacokinetics of Hydroxyprogesterone Caproate and its Primary Metabolites during Pregnancy
por: Boggess, Kim A., et al.
Publicado: (2018) -
The Influence of Prior Obstetrical History on Current 17-Hydroxyprogesterone Caproate Use
por: Ransom, Carla E., et al.
Publicado: (2011)